Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Yeah good point and sunrise is just a tiny portion of the income anyhow. Hope it attracts mucho attention! Public awareness is what we need! Imo
Actually hope it brings a lawsuit at this point. Let’s do this and get THE PEOPLE involved! World wide attention let’s go!
Such bullshit. Wow they are so scared of being sidelined. Funny on the timing too of course. This shit is so corrupt. Not selling a share. Pos fda and government.
Oh WOW! Great job USRM! KEEPS GETTING BIGGER AND BETTER! ;) love this company $USRM
Buy em up ;) LMAO! Cheers
International Stem Cell Corporation Granted Key Patent in US
Release: 5/7/2018 8:30:00 AM
CARLSBAD, Calif., May 07, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based biotechnology company developing novel stem cell based therapies and biomedical products, announced today that the United States Patent and Trademark Office (USPTO) has granted the Company a key patent (US9926529B2) on the method used to manufacture ISC-hpNSC. These are the cells administered in ISCO's ongoing Parkinson's disease clinical trial, and they can potentially be utilized in therapies to treat traumatic brain injury and stroke. This patent covers the procedure where human pluripotent stem cells (hpSCs), which have the potential to differentiate into essentially all cell types in the human body, are chemically differentiated into neural stem cells (NSCs), self-renewing cells that generate the neurons and glia of the central nervous system.
The new technique developed by ISCO's scientists outperforms the traditional methods because it produces a more pure population of NSCs, generating NSCs that are over 95% pure, as opposed to traditional methods that only yield purities of around 80%. In addition, ISCO's method is automatable and less labor intensive.
"Year after year, ISCO continues to strengthen its position as a leader in the field of regenerative medicine and explore the full potential of hpSCs," said Russell Kern, PhD, ISCO's Executive Vice President and Chief Scientific Officer. "This new patent adds to the strong intellectual property of the company and positions us to extend our scientific reach to new heights," he continues.
Generating NSCs from hpSCs has proved to be a scalable method that is easily adapted for manufacturing under GMP (Good Manufacturing Practices). With this method, ISCO has developed both master and working cell banks of ISC-hpNSC® under GMP. These banks have undergone quality control release testing for sterility, purity, identity, potency, and safety before being utilized in the clinic.
The cells manufactured through this process are absent of residual pluripotent stem cells, have a normal karyotype and are negative for bacteria, fungal, mycoplasmal, and adventitious viral contaminants, which is critical to assure their safe use in the clinic.
ISCO also conducted a series of pre-clinical studies with these cells and demonstrated the absence of teratomas and tumorigenic cells, and these findings have been published in various prestigious peer-reviewed journals. This shows that the cells are not associated with any proliferative risk or other serious adverse event, which is critical for the translation of ISC-hpNSC® into viable therapies that could potentially be delivered to millions of patients suffering from Parkinson's disease and other neurological diseases around the world.
About the clinical study
The Phase I clinical study is a dose escalation safety and preliminary efficacy study of ISC-hpNSC®, intracranially transplanted into patients with moderate Parkinson's disease. The open-label, single center, uncontrolled clinical trial will evaluate three different dose regimens of 30,000,000 to 70,000,000 neural cells. A total of 12 participants with moderate-to-severe Parkinson's disease will be treated. Following transplantation, the patients will be monitored for 12 months at specified intervals to evaluate the safety and biologic activity of ISC-hpNSC®. A PET scan will be performed at baseline, as part of the screening assessment, and at 6 and 12 months after surgical intervention. Clinical responses compared to baseline after the administration of ISC-hpNSC® will be evaluated using various neurological assessments such as Unified Parkinson Disease Rating Scale (UPDRS), Hoehn and Yahr and other rating scales. An extension phase of the study will evaluate patients every 6 months for 5 additional years.
About Parkinson's disease
Parkinson's disease is a degenerative disorder of the central nervous system mainly affecting the motor system. The motor symptoms of Parkinson's disease result from the death of dopamine-generating cells in the substantia nigra, a region of the midbrain. Early in the course of the disease, the most obvious symptoms are movement-related. These symptoms include shaking, rigidity, slowness of movement and difficulty with walking and gait. Later, thinking and behavioral problems may arise, with dementia commonly occurring in the advanced stages of the disease, and depression as the most common psychiatric symptom. Parkinson's disease is more common in people over the age of 50.
There are no approved treatments that restore the damaged dopaminergic neurons. Medications typically used in the treatment of Parkinson's disease, levodopa and dopamine agonists, improve the early symptoms of the disease. As the disease progresses and dopaminergic neurons continue to be lost, the drugs eventually become ineffective, while at the same time frequently producing a complication marked by involuntary writhing movements. There are over 10 million people afflicted by Parkinson's disease worldwide. In 2013 Parkinson's disease resulted in about 103,000 deaths globally, up from 44,000 deaths in 1990.
About ISC-hpNSC®
International Stem Cell Corporation's proprietary ISC-hpNSC® consists of a highly pure population of neural stem cells derived from human parthenogenetic stem cells. ISC-hpNSC® is a suspension of clinical grade cells manufactured under cGMP conditions that have undergone stringent quality control measures and are clear of any microbial and viral contaminants. Preclinical studies in rodents and non-human primates have shown improvement in Parkinson's disease symptoms and increase in brain dopamine levels following the intracranial administration of ISC-hpNSC®. ISC-hpNSC® provides neurotrophic support and neuroregeneration to the dying dopaminergic neurons of the recipient Parkinson's disease brain. Additionally, ISC-hpNSC® is safe, well tolerated and does not cause adverse events such as dyskinesia, systemic toxicity or tumors in preclinical models. International Stem Cell Corporation believes that ISC-hpNSC® may have broad therapeutic applications for many neurological diseases affecting the brain, the spinal cord and the eye.
About International Stem Cell Corporation
International Stem Cell Corporation (ISCO) is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments, clinical studies expectations (including timing and results), progress of research and development, the potential use of ISC-hpNSC in other therapies and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain future capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the company's business, particularly those mentioned in the cautionary statements found in the company's Securities and Exchange Commission filings. The company disclaims any intent or obligation to update forward-looking statements.
International Stem Cell Corporation
Russell Kern, PhD
Executive Vice President, CSO
(760) 940-6383
ir@intlstemcell.com
Primary Logo
CARLSBAD, Calif., April 10, 2018 (GLOBE NEWSWIRE) -- International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company"), a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ending on December 31, 2017.
"In 2017 we made significant progress towards our business unit optimization and have managed to decrease operating cash burn by nearly fifty percent, all while conducting the world's first clinical trial of neural stem cells in Parkinson's disease patients. We recently completed stem cell transplantation in the second cohort of our patients and expect to initiate phase II before year's end" stated Andrey Semechkin, Ph.D., CEO and Co-Chairman of ISCO. "We still face challenges, but I believe that our cutting-edge therapy and innovative commercial products, as well as seasoned executive team, will lead us to future success," he continued.
FY 2017 Financial highlights:
• Revenues increased to $7.5 million in 2017 compared to $7.2 million in 2016 ;
• Combined operating income for the year ended December 31, 2017 from our two wholly owned revenue generating subsidiaries, Lifeline Cell Technology and Lifeline Skin Care, was $1.4 million, compared to $1.3 million in 2016
• Average net cash used in operating activities was approximately $179,000 per month for the year ended December 31, 2017, a decrease of 49%, compared to $350,000 in 2016;
• Gross margins declined 1% year over year to 72% in 2017, compared to 73% in 2016
Recent Corporate Highlights
• The second cohort of patients in the clinical trial for Parkinson's disease was successfully transplanted with 50,000,000 ISC-hpNSC® cells
• 13 pending patent applications covering internally-generated and in-licensed technologies were issued as patents
2018 Anticipated Events
• Complete dosing patients in phase I Parkinson's disease clinical trial
• Announce full safety results from the first cohort of patients currently in phase I of the Parkinson's disease clinical trial
• Commence phase II clinical study of ISC-hpNSC® for the treatment of Parkinson's disease
• Initiate phase II clinical study of ISC-hpNSC® for the treatment of traumatic brain injury
• Publish pre-clinical data for traumatic brain injury program
• Receipt of US patent for manufacturing ISC-hpNSC®
Presentations
In 2017, the Company presented positive interim results of its clinical trial in Parkinson's disease at the following events:
• The American Society for Neural Therapy and Repair Annual Meeting;
• The American Society of Gene and Cell Therapy 20th Annual Meeting;
• The Society for Neuroscience Annual Meeting (Neuroscience 2017).
About International Stem Cell Corporation
International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial background with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell™. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com). More information is available at www.internationalstemcell.com.
To subscribe to receive ongoing corporate communications, please click on the following link:
http://www.b2i.us/irpass.asp?BzID=1468&to=ea&s=0
To like our Facebook page or follow us on Twitter for company updates and industry related news, visit: www.facebook.com/InternationalStemCellCorporation and www.twitter.com/intlstemcell
Safe harbor statement
Statements pertaining to anticipated developments and company achievements, expected clinical studies (including timing and results), progress of research and development, and other opportunities for the company and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact (including, but not limited to statements that contain words such as "will," "believes," "plans," "anticipates," "expects," "estimates,") should also be considered to be forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, regulatory approvals, need and ability to obtain capital, application of capital resources among competing uses, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the Company's business, particularly those mentioned in the cautionary statements found in the Company's Securities and Exchange Commission filings. The Company disclaims any intent or obligation to update forward-looking statements.
Vert and cdel trying to cover. Buy em up before they do. Imo.
Future of medicine. Long and strong!
#StemCellDreamTeamUSRM
It’s being purposely held down to accumulate right now IMO. Looks at the accumulation line on the charts. If even a decent amount of volume came in right now we would move fast. I won’t be on the sidelines and feel very comfortable with my position. All Imo. Cheers $ISCO
I’m not assuming it’s 30 million because it’s not. I don’t see any sign of dilution coming through. There can be a spark within the company or industry that sends this flying right now!! This one will move very fast with volume. All imo.
Folks do your own DD.
ISCO - OTCQB
International Stem Cell Corp.
http://internationalstemcell.com/company/
—————
Press Releases
http://investors.internationalstemcell.com/Press_Releases
—————-
Pipeline
http://internationalstemcell.com/pipeline/
————
https://www.otcmarkets.com/stock/ISCO/overview
COMPANY DESCRIPTION
<p>International Stem Cell Corporation is focused on the therapeutic applications of human parthenogenetic stem cells (hpSCs) and the development and commercialization of cell-based research and cosmetic products. ISCO's core technology, parthenogenesis, results in the creation of pluripotent human stem cells from unfertilized oocytes (eggs). hpSCs avoid ethical issues associated with the use or destruction of viable human embryos. ISCO scientists have created the first parthenogenetic, homozygous stem cell line that can be a source of therapeutic cells for hundreds of millions of individuals of differing genders, ages and racial backgrounds, with minimal immune rejection after transplantation. hpSCs offer the potential to create the first true stem cell bank, UniStemCell?. ISCO also produces and markets specialized cells and growth media for therapeutic research worldwide through its subsidiary Lifeline Cell Technology (www.lifelinecelltech.com), and stem cell-based skin care products through its subsidiary Lifeline Skin Care (www.lifelineskincare.com).</p>
————
https://backend.otcmarkets.com/otcapi/company/sec-filings/12378955/content/html
https://www.lifelineskincare.com/
Cosmetic Market – Sk in Care Products. Our wholly-owned subsidiary Lifeline Skin Care, Inc. (“LSC”) develops, manufactures and offers for sale cosmetic skin care products based on two core technologies: encapsulated extract derived from our pluripotent human non-embryonic stem cells and specially selected small molecules. Products containing stem cell technology include: Defensive Day Serum, Recovery Night Serum, Firming Eye Complex, Neck Firming Complex, Aqueous Gel Serum, Intense Moisture Serum, and ProPLUS Advanced Aqueous T reatment. Products based on the proprietary small molecule technology include: Molecular Renewal Serum, Brightening Toner, and ProPLUS Molecular Renewal Treatment. LSC’s products are regulated as cosmetics. LSC’s products are sold domestically through a br anded website, and through the professional channel (including dermatologists, plastic surgeons, medical, day and resort spas). Domestically, we plan to increase sales of our products by expanding our product line and increasing brand awareness through adv ertising, sales promotion and public relations. Internationally, we are actively evaluating potential distribution partnerships with major skincare and beauty distributors in Asia and Australia.
https://www.lifelinecelltech.com/
Biomedical Market – Primary Human Cell Research Products. Our wholly-owned subsidiary Lifeline Cell Technology, LLC (“LCT”) develops, manufactures and commercializes over 175 human cell culture products, including frozen human “primary” cells and the reagents (called “media”) needed to grow, maintain and differentiate the cells. LCT’s scientists have used a technology called basal medium optimization to systematically produce optimized products designed to culture specific human cell types and to elicit specific cellular behaviors. These techniques also produce products that do not contain non-human animal proteins, a feature desirable to the research and therapeutic markets. Each LCT cell product is quality tested for the expression of specific markers (to assure the cells are the correct type), proliferation rate, viability, morphology and absence of pathogens. Each cell system also contains associated donor information and all informed consent requirements are strictly followed. LCT’s research products are marketed and sold by its internal sales force, OEM partners and LCT brand distributors in Europe, Australia, and Asia.
Cyto Therapeutics was registered in the state of Victoria, in December 2014 for the purposes of conducting clinical trials in Australia. Cyto Therapeutics is a limited proprietary company and a wholly-owned subsidiary of ISCO.
Who cares maybe he didn’t like his Russian name. Work harder. LOL
That’s right! The chart does look set to turn and I see nothing diluting. Could make a run at anytime with the low o/s! We’ll see. Fingers crossed. Go $ISCO!
Thanks again!! Yeah I have not bet the farm :) and will add average down if needed. I see much more upside than downside here though even with dilution potential. Once the world realizes how big regenerative medicine is going to be this will take off on that alone. Not sure what the catalyst will be but it’s coming one day. Maybe it’s fda getting out the way and/or insurance companies approving procedures.
Per the brilliant billionaire Dr. Murphy (sold cordis Corp to J & J, small parts inc that eventually acquired by amazon, has like 17 patents and is chair of another stem cell company) in the docuseries the healing miracle “stem cells will change medicine like antibiotics did”!!. Tick..tock
$ISCO
Great post thanks! I have researched many regenerative medicine companies in the last few years. I really like the subsidiaries (very rare to find in this space) and the tech here! I believe it has a great chance of becoming a giant or getting acquired. I’ve placed my bet and will continue to add along the way!
$ISCO
Yup keep loading too!! This is the start and going to get bigger and better! Exciting times ahead!
Yup folks want shares bad and are willing to go to great lengths to obtain them. Buy what you can before the boom imo. Face of regenerative meds here! $$USRM
Buy em up! ;)
$ISCO
WOWZA! Look at that accumulation line! Someone seems to be collecting shares the last year and half :))!
http://schrts.co/kzmMXH
If it does I’ll buy more! ;))) Cheers
FUTURE OF MEDICINE! Massive nothing going on really LOL!
$$$$ISCO
http://internationalstemcell.com/pipeline/
Looks like they have to me. ;)
Great news today! Agreed that it is way undervalued. Sleeper here! Load em up while you can imo.
$ISCO
HUGE LOADING ZONE! OVERSOLD! ANYONE OFF THEIR ROCKER AND SELLING HERE YOU SHOULD SCOOP!
6 million shares is not 5 percent of o/s. :p plus those were sold 1-22 to a group of folks. Does a form submission mean they are dropped into the market :p. NO! Maybe the same private investors with ownership in sunrise are the buyers.
Yup :))!! New Silicon Valley Trend: Freeze Your Stem Cells For $7K
Forever Labs in California is getting a lot of business from tech workers who want to extend their lifespan down the line by freezing their stem cells for $7,000 a shot. Good to know a guy who wrote some code for Candy Crush will outlive the rest of us.
http://theinterrobang.com/new-silicon-valley-trend-freeze-stem-cells-7k/
Yuppers by a billionaire that founded Small Parts Inc. that was eventually acquired by AMAZON and the founder of Cordis Corp. that was acquired by JOHNSON & JOHNSON.
Just an okay track record LMAO!
I agree that this will go back on the Nasdaq if not acquired imo!
The numbers and industry are really starting to ramp up right now! Excited for the Q coming out here! Grabbing a few more this week!
$$$USRM
Stem Cell Testimonials and info:
http://usstemcellclinic.com/testimonials/
Joe Rogan Experience~ Mel Gibson on his dad getting stem cells
Good maybe he is realizing how big it’s going to be and starting to back peddle now! Or just off the pay list now :). Thanks for the info.
Who knows why he sold those shares. I’m sure he has his reasons though. Maybe making the books even more appealing for upcoming Q or to attract a big investor?!
No and don’t care to because 100% guarantee he is a paid pusher for big pharmas crap.
Lets inform the not paid and see what they say...Oh wait we know what the people say. Safe and effective!
Pharma pays off jounalists, politicians and even talk show hosts. Only ones talking shit are the ones that are paid too, scared of losing money or want they want shares!
Eom
Not a big of deal imo.
Looking forward to the next Q!
$$USRM
If you blow that date, don’t freak out, but consider your options. If you file it late, what’s the consequence? Generally it means nothing, but sometimes there are penalties and fees attached to it.
https://www.quora.com/What-does-one-do-if-one-forgets-to-file-SEC-Form-D-after-the-15-day-limit-for-private-security-sales
Boy gets new skin from his own stem cells.
Jack Nicklaus golf legend!
“I'm not a doctor, but I think that stem cell is going to change... the direction of orthopedics, totally."
https://www.google.com/amp/s/amp.cnn.com/cnn/2018/04/27/health/jack-nicklaus-stem-cell-therapy/index.html
John Salley success story
Notably, the FDA will be incorporating some “new concepts for how small investigators and firms can seek and meet the approval standard for products through efficient expedited pathways.” This is a step in the right direction.
How exactly will this work in practice? No one really knows. Marks and Gottlieb only provide one theoretical example: the FDA will provide “tools” to allow small firms to work collaboratively to obtain a biologics license for physicians, researchers and clinics.
https://www.painnewsnetwork.org/stories/2018/3/9/fda-moves-forward-on-stem-cells
—————-
Even though we shouldn’t even need the pathetic greedy fda it would help spread the word that regenerative medicine is the real deal. It will come sooner than later with them I feel until that time usrm will continue to grow it’s business in a fast way! There is no turning back because it’s to far along and to well known to the world now! Fda are just figuring out how their greedy asses can make money on it. Maybe through licenses it sounds to me?! Tick tock...Just be loaded always because there is to much going on here and at such a discount! Really great posts today longs! All imo.
$$$USRM
You see the start. No one is selling. It’s shorty trying to manipulate through cdel and cant. Take their shares!
They are working hard right now trying to shake shares and Longs just holding tight. Let them keep sellin’ and stackin’ shares because they will need to cover at some point. Buy em up because they are providing the opportunity here. These are not longs selling here. A catalyst will burn shorty. Very oversold so buy any offered up. All imo. Eom
$$$USRM
One final thought for the weekend actually. I wonder what are pps will be when this hits 100 million in annual sales?! There is no doubt in my mind it will get there just a matter of when. Maybe 3-5 years but not sure of course. I feel we will continue to go up up and away until multiple rocket ships start grabbing us and one of those will be when insurance comes along and gives a 50-100x boost in revs and pps. Big money is smart front loading (not that I like the tactics!) we should be all doing the same and I know a lot of us are ;). IMO
Yes sir A1 that accumulation line is through the roof still! This stock is being carefully front loaded in a big way. Imo the most patient will win here because once they have their percentage they want we are off to the races. Or a huge catalysts could hit at any time. Either way tick tock as many say and I’m sure are right. Imo. Have a good rest of the weekend.